Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Opdivo (nivolumab) Disease area(s): Oncology Manufacturer(s): Bristol Myers Squibb 2024 Sales (USD): $9.30 billion Why it sold so well: BMSs flagship immunotherapy, Opdivo, achieved strong sales in 2024 due to several key factors
Reduction in Visceral Fat Tesamorelin has shown impressive reductions in abdominal visceral fat , particularly in HIV-related lipodystrophy but also in non-HIV populations
Samuolien et al
Hyperpigmentation mechanism of methyl 3,5-di-caffeoylquinate through activation of p38 and MITF induction of tyrosinase
Find out what the research shows below
US$ 24.41
US$ 21.10
US$ 26.63
US$ 22.83
US$ 25.99
US$ 3374.25
Sold : Login>>